Dr. Sebastian Bauer

Home/Tag: Dr. Sebastian Bauer

CTOS Provides International Networking Opportunities

Executive Director Norman Scherzer traveled to Lisbon, Portugal in November to attend the 21st annual meeting of the Connective Tissue Oncology Society (CTOS). CTOS is an annual conference which has grown since its inception [...]

By |2019-09-20T15:29:40-04:00November 28th, 2016|Events, Newsletter, Research|

Sebastian Bauer Awarded the 2015 GIST Group Switzerland Science Prize

LRG research team member, Dr. Sebastian Bauer recently received the 6th Annual Science Prize awarded by the GIST Group Switzerland on November 26, 2015 at the semi-annual meeting of the Swiss Group for Clinical [...]

By |2019-09-20T15:39:33-04:00December 16th, 2015|Newsletter, Research|

Update on Potential Treatments for Imatinib-Resistant GIST

In a recent article entitled "Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions" published online in Springer for Research and Development,  LRG Research Team member Sebastian Bauer [...]

By |2019-10-31T12:01:30-04:00July 31st, 2015|News, Research|

Novartis Gains Approval for Panobinostat

Novartis Pharmaceuticals recently received FDA approval for panobinostat, a blood cancer drug that targets multiple myeloma. This was a surprising ruling, as it was a turnaround from last year’s Oncologic Drugs Advisory Committee’s 5-2 [...]

By |2019-04-08T09:34:28-04:00March 9th, 2015|Clinical Trials, Drug Treatment, News|

New Horizons Takes Place in Zurich, Switzerland

With the beautiful mountains of Switzerland and Lake Zurich in the background, 44 GIST Patient representatives from 28 countries and 32 patient groups/organizations convened in Zurich for the New Horizons GIST meeting from May 14-17, 2014.

By |2019-09-20T15:49:04-04:00July 2nd, 2014|Advocacy, Events, GIST Education, Global, News|

Complete Resection May Result in Long-Term GIST Survival

The results of a retrospective study indicated that patients with metastatic gastrointestinal stromal tumors (GIST) who are able to achieve complete macroscopic surgical resection of their disease may be able to achieve long-term survival.

By |2019-09-20T15:47:08-04:00April 2nd, 2014|News, Research, Surgery|

2013 LRG Research Team Progress Report

Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.

LRG & colleagues make their mark on 17th annual CTOS meeting in Prague

Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.

By |2019-09-20T13:18:16-04:00February 1st, 2013|Events, News|

Understanding How GISTs Develop Enables Discovery of New Therapies

By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team   Researchers talk plainly about microGISTs, how this cancer develops and what all [...]

By |2019-09-20T13:22:48-04:00January 23rd, 2013|Clinical Trials, Diagnosis, GIST Education, Mutations, News, Research|
Go to Top